5-Azacytidine/Azacitidine
Authors:
- Antonia MüllerAMAntonia Müller
- Mareike FlorekMFMareike Florek
- 7 October 2009
- book chapter
- Published by Springer Nature
- Vol. 184, 159-170
Abstract
5-Azacytidine is a pyrimidine nucleoside analog that has been discovered more than 40 years ago. Despite remarkable responses in the treatment of acute myeloid leukemias in the 1970s no earlier than 2004 has this agent been approved by the US FDA for the treatment of all subtypes of myelodysplatic syndromes (MDS). For the first time a drug was proven to alter the natural course of MDS, as demonstrated in three clinical trials conducted by the CALG B. Complete remission rates ranged between 10–17%, and more recently, a significant survival benefit for MDS patients treated with 5-Azacytidine could be established. The antineoplastic activity is due to incorporation into RNA with disruption of RNA metabolism, and inhibition of DNA methylation. Strategies of combining epigenetic manipulation with other ‘new’ drugs aim at increasing the efficacy of the hypomethylating agents. Particularly histone deacetylase inhibitors have been deemed useful therapeutic partners, and preliminary results are promising.Keywords
This publication has 50 references indexed in Scilit:
- Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic SyndromesJournal of Clinical Oncology, 2008
- A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblastsCell Cycle, 2008
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trialLeukemia & Lymphoma, 2008
- DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic SyndromesSeminars in Hematology, 2008
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood, 2007
- Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head groupInternational Journal of Cancer, 2007
- Epigenetic Control of the foxp3 Locus in Regulatory T CellsPLOS Biology, 2007
- Targeting Hypomethylation of DNA to Achieve Cellular Differentiation in Myelodysplastic Syndromes (MDS)The Oncologist, 2001
- Mechanism of action of eukaryotic DNA methyltransferaseJournal of Molecular Biology, 1982